Print
Email
Print Edition StoriesWednesday, February 3, 2010
Syndax Pharmaceuticals pulls in $9M tranche
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
Syndax Pharmaceuticals Inc., a developer of anti-cancer treatments, has raised $9 million of a planned $16 million securities offering, according to a filing with the U.S. Securities and Exchange Commission.
The Waltham-based company last reported receiving funding in April 2007, when it closed on a $40 million Series A financing round, co-led by Domain Associates and MPM Capital, with additional backing by Avalon Ventures, Forward Ventures and Pappas Ventures. The VC rounds supported the advancement of a Syndax epigenetic drug for cancer into midstage clinical trials. At the time, CEO Joanna Horobin said the funding would also support the company’s growth from five employees to 10 employees.
Syndax was co-founded in San Diego in 2005 by Eckard Weber of Domain Associates, and Ronald Evans of the Salk Institute for Biological Studies and Howard Hughes Medical Institute. It was founded with an exclusive license from the Salk Institute for the IP from Evans’ research on histone deacetylase (HDAC) inhibition and the regulation of nuclear receptors.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
